Log in
NASDAQ:ARGX

argenx Stock Forecast, Price & News

$281.59
+16.11 (+6.07 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$274.77
Now: $281.59
$281.68
50-Day Range
$248.13
MA: $263.12
$280.53
52-Week Range
$103.75
Now: $281.59
$284.00
Volume79,115 shs
Average Volume173,552 shs
Market Capitalization$13.24 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.04
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Read More
argenx logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.27 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARGX
CUSIPN/A
Phone329-310-3400
Employees186

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$78.17 million
Book Value$30.88 per share

Profitability

Miscellaneous

Market Cap$13.24 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$281.59
+16.11 (+6.07 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











argenx (NASDAQ:ARGX) Frequently Asked Questions

How has argenx's stock price been impacted by Coronavirus (COVID-19)?

argenx's stock was trading at $133.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ARGX stock has increased by 110.4% and is now trading at $281.59.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of argenx?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 4 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for argenx
.

What stocks does MarketBeat like better than argenx?

Wall Street analysts have given argenx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but argenx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is argenx's next earnings date?

argenx is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for argenx
.

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) released its quarterly earnings results on Thursday, October, 22nd. The company reported ($3.96) earnings per share for the quarter, missing the Zacks' consensus estimate of ($2.80) by $1.16. The company earned $8.97 million during the quarter, compared to analyst estimates of $18.08 million.
View argenx's earnings history
.

What price target have analysts set for ARGX?

19 brokerages have issued 1 year price objectives for argenx's shares. Their forecasts range from $160.00 to $300.00. On average, they expect argenx's stock price to reach $248.31 in the next year. This suggests that the stock has a possible downside of 11.8%.
View analysts' price targets for argenx
.

Who are some of argenx's key competitors?

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

Who are argenx's key executives?

argenx's management team includes the following people:
  • Mr. Timothy Van Hauwermeiren M.B.A., M.Sc., MSc, EMBA, CEO & Exec. Director (Age 48)
  • Mr. Eric Castaldi, Chief Financial Officer (Age 56)
  • Mr. R. Keith Woods, Chief Operating Officer (Age 52)
  • Prof. Hans de Haard, Chief Scientific Officer (Age 60)
  • Mr. Dirk Marcel Leon Beeusaert L.L.M., Gen. Counsel (Age 56)
  • Mr. Arjen Lemmen M.Sc., VP of Corp. Devel. & Strategy (Age 35)
  • Dr. Wim Parys M.D., Chief Medical Officer (Age 60)
  • Joke Comijn, Director Corp. Communications & Investor Relations (EU)
  • Mr. Marc Schorpion, Global Head of HR
  • Ms. Andria Wilk, Global Head of Quality Assurance

When did argenx IPO?

(ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is argenx's stock symbol?

argenx trades on the NASDAQ under the ticker symbol "ARGX."

Who are argenx's major shareholders?

argenx's stock is owned by many different retail and institutional investors. Top institutional investors include Federated Hermes Inc. (1.00%), Jennison Associates LLC (0.91%), BlackRock Inc. (0.80%), Lord Abbett & CO. LLC (0.47%), New York State Common Retirement Fund (0.27%) and TD Asset Management Inc. (0.24%).

Which major investors are selling argenx stock?

ARGX stock was sold by a variety of institutional investors in the last quarter, including Indus Capital Partners LLC, Lord Abbett & CO. LLC, Samlyn Capital LLC, ArrowMark Colorado Holdings LLC, Morgan Stanley, Jennison Associates LLC, Candriam Luxembourg S.C.A., and UBS Asset Management Americas Inc..

Which major investors are buying argenx stock?

ARGX stock was acquired by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, State Street Corp, Voloridge Investment Management LLC, Williams Jones Wealth Management LLC., BlackRock Inc., Sei Investments Co., Assenagon Asset Management S.A., and Aperio Group LLC.

How do I buy shares of argenx?

Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is argenx's stock price today?

One share of ARGX stock can currently be purchased for approximately $281.59.

How big of a company is argenx?

argenx has a market capitalization of $13.24 billion and generates $78.17 million in revenue each year. The company earns $-182,520,000.00 in net income (profit) each year or ($4.73) on an earnings per share basis. argenx employs 186 workers across the globe.

What is argenx's official website?

The official website for argenx is www.argenx.com.

How can I contact argenx?

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at 329-310-3400 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.